Pharmaceuticals, Biotechnology & Life Sciences

Meta description:

Vertex Pharmaceuticals’ latest R&D momentum, driven by Trikafta’s growth and oncology pipeline, sparks a bullish outlook—yet patent cliffs, rising R&D spend and regulatory pressures loom.

Biogen’s Q4 earnings hit, high‑dose SPINRAZA approval, and patent‑cliff strategy reveal how the biotech giant balances R&D costs, market access and M&A to protect revenue and stay ahead of rivals in neurology.

Orion’s Nubeqa sales projected to top €1 billion, driven by solid phase III data, EU approvals and high‑margin oncology revenue growth.

Regeneron’s latest J.P. Morgan Healthcare Conference updates reveal gene‑editing therapy for hearing loss, a promising weight‑loss dual agonist, and expanded Eylea indications, boosting investor confidence and market prospects.

Eurofins Scientific’s recent EMAR insider filings show strong regulatory compliance, resilient shares, and a growing digital‑testing strategy amid European market volatility.

Argenx shares swing after FDA grants priority review for Vyvgart’s new myasthenia gravis indication, boosting outlook and revealing the company’s strategy to diversify beyond oncology.

Roche Holding AG’s bold obesity and YL201 moves spotlight a rare diagnostics‑therapeutics synergy—explore how this could reshape its revenue and risk profile.

Deutsche Bank downgrades Haleon PLC to sell, citing slower earnings and rising costs; other analysts stay neutral, highlighting resilience and potential for strategic moves.

IPSEN’s IPN60340 earns FDA Breakthrough Therapy status for AML, delivering 58 % response in patients unsuitable for intensive chemo—plus promising Parkinson’s data from EPITOME.